Formulation and Evaluation of Microsponges-loaded Transdermal Gel for the Management of Osteoarthritis.

IF 1.2 Q4 PHARMACOLOGY & PHARMACY
Shiwani Sen, Anjali Sharma, Priyanka Kriplani, Hitesh Malhotra, Vishnu Mittal
{"title":"Formulation and Evaluation of Microsponges-loaded Transdermal Gel for the Management of Osteoarthritis.","authors":"Shiwani Sen, Anjali Sharma, Priyanka Kriplani, Hitesh Malhotra, Vishnu Mittal","doi":"10.2174/0127722708297654240718053117","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Osteoarthritis (OA) stands as the most widespread form of arthritis, representing a primary source of pain and functional impairment among the elderly. It is often referred to as a degenerative joint disease. OA is more than just wear and tear; it is an aberrant remodelling of joint tissues prompted by a deluge of inflammatory mediators released within the compromised joint. This disease affects 15 million people in India annually.</p><p><strong>Objective: </strong>Aceclofenac is a COX-2 inhibitor that has anti-inflammatory activity. However, aceclofenac has a short mean plasma elimination half-life and poor water solubility. It requires frequent dosing, which has been linked to a number of negative side effects, including bleeding and gastrointestinal irritation. A potential solution to this problem is the transdermal administration of aceclofenac using microsponges. In order to have a synergistic effect along with the bioenhancer effects, piperine was incorporated into the formulation.</p><p><strong>Methods: </strong>Microsponges were created using the quasi-emulsion solvent diffusion method. After characterization, the prepared microsponges were incorporated into the Carbopol gel. The <i>in vivo</i> study focused on evaluating the optimized formulation, F1.</p><p><strong>Results: </strong>All the prepared microsponge formulations underwent assessment based on parameters including yield of production, entrapment efficiency, and <i>in vitro</i> drug release. The outcomes indicated that batches ranging from F1 to F9 showed positive entrapment efficiency and <i>in vitro</i> drug release. From 50.37% to 80.76 % and 71.18% to 91.8% and <i>in vivo</i> studies the results reveal that the inflammatory cells in the best formulation Ace(B) group were reduced hence the formulation's anti-inflammatory impact was achieved.</p><p><strong>Conclusion: </strong>The findings indicate that Formulation F1 exhibits superior entrapment and enhanced drug release. The kinetics study suggests that the optimized formulation aligns well with the Higuchi model and adheres to the Fickian transport drug release mechanism. Animal study findings suggest that optimized formulation Ace(B) may possess ideal -anti-osteoarthritic activity for osteoarthritic disease. Further clinical trials on humans may be conducted in order to make the research fruitful for society.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":"19 1","pages":"79-99"},"PeriodicalIF":1.2000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recent Advances in Inflammation & Allergy Drug Discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0127722708297654240718053117","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Osteoarthritis (OA) stands as the most widespread form of arthritis, representing a primary source of pain and functional impairment among the elderly. It is often referred to as a degenerative joint disease. OA is more than just wear and tear; it is an aberrant remodelling of joint tissues prompted by a deluge of inflammatory mediators released within the compromised joint. This disease affects 15 million people in India annually.

Objective: Aceclofenac is a COX-2 inhibitor that has anti-inflammatory activity. However, aceclofenac has a short mean plasma elimination half-life and poor water solubility. It requires frequent dosing, which has been linked to a number of negative side effects, including bleeding and gastrointestinal irritation. A potential solution to this problem is the transdermal administration of aceclofenac using microsponges. In order to have a synergistic effect along with the bioenhancer effects, piperine was incorporated into the formulation.

Methods: Microsponges were created using the quasi-emulsion solvent diffusion method. After characterization, the prepared microsponges were incorporated into the Carbopol gel. The in vivo study focused on evaluating the optimized formulation, F1.

Results: All the prepared microsponge formulations underwent assessment based on parameters including yield of production, entrapment efficiency, and in vitro drug release. The outcomes indicated that batches ranging from F1 to F9 showed positive entrapment efficiency and in vitro drug release. From 50.37% to 80.76 % and 71.18% to 91.8% and in vivo studies the results reveal that the inflammatory cells in the best formulation Ace(B) group were reduced hence the formulation's anti-inflammatory impact was achieved.

Conclusion: The findings indicate that Formulation F1 exhibits superior entrapment and enhanced drug release. The kinetics study suggests that the optimized formulation aligns well with the Higuchi model and adheres to the Fickian transport drug release mechanism. Animal study findings suggest that optimized formulation Ace(B) may possess ideal -anti-osteoarthritic activity for osteoarthritic disease. Further clinical trials on humans may be conducted in order to make the research fruitful for society.

微海绵透皮凝胶治疗骨关节炎的配方及评价。
背景:骨关节炎(OA)是最普遍的关节炎形式,是老年人疼痛和功能障碍的主要来源。它通常被称为退行性关节疾病。OA不仅仅是磨损;这是一种异常的关节组织重塑,是由受损关节内释放的大量炎症介质引起的。这种疾病每年影响印度1500万人。目的:乙酰氯芬酸是一种具有抗炎活性的COX-2抑制剂。然而,乙酰氯芬酸的平均血浆消除半衰期短,水溶性差。它需要频繁给药,这与许多负面副作用有关,包括出血和胃肠道刺激。这个问题的一个潜在解决方案是使用微海绵经皮给药。为了与生物增强剂协同作用,在配方中加入了胡椒碱。方法:采用准乳状溶剂扩散法制备微海绵。表征完成后,将制备的微海绵加入到Carbopol凝胶中。体内研究重点是评价优化后的配方F1。结果:对制备的微海绵制剂进行了产率、包封效率、体外释药等指标的评价。结果表明,F1 ~ F9批的包封效率和体外释药率均为正。从50.37%到80.76%,从71.18%到91.8%,体内研究结果表明,最佳配方Ace(B)组炎症细胞减少,达到抗炎作用。结论:F1配方具有良好的包埋性和增强的释药效果。动力学研究表明,优化后的制剂符合Higuchi模型,符合Fickian转运释药机制。动物实验结果表明,优化后的Ace(B)配方对骨关节炎具有理想的抗骨关节炎活性。为了使这项研究为社会带来成果,可能会进行进一步的人体临床试验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.30
自引率
0.00%
发文量
33
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信